This is an HTML version of an attachment to the Freedom of Information request 'Documents relating to EU-US trade talks (since July 2018)'.

Ref. Ares(2019)2527775 - 10/04/2019
From:  [Art 4.1(b)]
Sent: Thursday, September 06, 2018 5:44 PM 
To:  [Art 4.1(b)]  (TRADE);  [Art 4.1(b)]  (TRADE); [Art 4.1(b)]  (TRADE);  [Art 4.1(b)]  (TRADE) 
Cc:  [Art 4.1(b)]
 (TRADE); [Art 4.1(b)]  (TRADE); VERLY Johan (CAB-MALMSTROM); 
Subject: FLASH: meeting HoC Mia Åsenius and Eli Lilly  [Art 4.1(b)]
Today Head of Cabinet Ms Åsenius met the  [Art  of Eli Lilly (a multinational pharmaceutical 
company) Mr  [Art 4.1(b)]  (
[Art 4.1(b)]

The main subject of the meeting was the EU-US trade relations, with a specific focus on the
intellectual property (IP). Overall, the pharma industry is one of the main advocates for a 
stronger EU-US cooperation.
[Art 4.1(a)]
[Art 4.1(b)]
hlighted that the pharma industry has one main interest in trade 
agreements – a strong IP chapter. Therefore, an EU-US agreement should also have such a 
chapter. Ms Åsenius explained that it is not foreseen to re-start TTIP negotiations and an 
agreement of more restricted scope would have more chances of being agreed.
The rest of the document is redacted as out of scope

[Art 4.1(b)]
 << OLE Object: Picture (Device Independent Bitmap) >> 
European Commission
Directorate General Trade 
Unit B3 Intellectual Property and Public Procurement
1049 Brussels, Belgium
office: CHAR [Ar
, tel.: +
t 4.1(b)] 32-2-2[Art 4.1(b)]
e-mail: [Art 4.1(b)]
The views expressed in this e-mail are my own and may not, 
under any circumstances, be interpreted as stating an official 
position of the European Commission.